Stay updated with breaking news from Natalee Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pooja Advani, MBBS, MD, details key advancements and the significance of pivotal trials that were presented by her colleagues at a recent OncLive® State of the Science Summit™ on breast cancer, which she chaired.
In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.
In her final discussion, Dr Moore analyzes key differences between the NATALEE and moncarchE trials.
Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.
Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.